#Taipei #USA #AnnJi Pharmaceutical #AJ201 #SBMA

AnnJi Pharmaceutical Moves Forward with AJ201

AnnJi Pharmaceutical Co., Ltd., a leader in innovative drug development, has received approval to advance its promising treatment, AJ201 (rosolutamide), into the pivotal phase III clinical study known as ROMA-KD. This trial targets spinal and bulbar muscular atrophy (SBMA), also referenced as Kennedy's disease. Phase III is the final stage of clinical trials before a drug can be submitted for approval by regulatory authorities such as the U.S. FDA.

AJ201 is the only experimental treatment currently progressing through phase III development worldwide specifically for SBMA, a hereditary neuromuscular condition that has no FDA-approved therapies. This development signifies a potential ray of hope for patients suffering from this debilitating disease.

Understanding SBMA and AJ201

SBMA is an inherited condition associated with progressive degeneration of motor neurons, affecting muscle strength and control. Symptoms can involve challenges with mobility, swallowing, and speech. As explained by Dr. Wendy Huang, CEO of AnnJi, "For those with SBMA, daily activities become increasingly difficult. Climbing stairs, feeding oneself, and even speaking can become monumental tasks. This disease impacts entire families across generations, with no approved FDA treatment in sight. The advancement of AJ201 to phase III brings us closer to changing that narrative, providing hope to those affected."

AJ201 is an oral small molecule that operates by clearing the pathogenic mutated androgen receptor protein, while enhancing cellular stress response pathways like Nrf1, Nrf2, and HSF1. As the first potential treatment of its class for SBMA, it has received Fast Track designation and orphan drug status from the FDA, as well as orphan drug designation in the EU. These designations expedite the development and review process for therapies aimed at treating serious conditions with unmet medical needs.

Trial Design and Patient Engagement

The phase III ROMA-KD trial will recruit approximately 200 patients globally, focusing heavily on the U.S. as a key region. This study is randomized, double-blind, and placebo-controlled to assess the efficacy and safety of AJ201 in symptomatic patients with SBMA who are capable of walking. The results from this extensive trial will inform potential regulatory submissions worldwide.

In a unique initiative aligning with its patient-centric approach, AnnJi has established a Patient and Caregiver Advisory Council for those impacted by SBMA. This council came into being during a collaboration with the Kennedy's Disease Association and aims to create an ongoing, constructive dialogue between the company and the SBMA community. The insights from patients and caregivers will guide AnnJi in research endeavors, study designs, and informational material to be utilized throughout the clinical trials.

Commitment to the SBMA Community

Commitment to transparency and collaboration underpins AnnJi's dedication to furthering the development of AJ201 for SBMA patients and their families. The company's approach involves active engagement with patients, caregivers, clinicians, and patient advocacy groups globally, ensuring that their voices and experiences inform the drug development process.

As we stand on the verge of potentially transformative outcomes for those suffering from SBMA, AnnJi Pharmaceutical is resolute in its mission to innovate treatments for chronic and rare diseases. With AJ201, the company is focused not just on developing a drug but on fostering hope and improving the quality of life for individuals facing the challenges of this rare condition.